Evidence map›Paper›PMID 40775186›Full record

ArticleDermatology and therapy2025

A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys.

Lauren C S Kole, Yayoi Tada, Sascha Gerdes, Alice B Gottlieb, Matthias Augustin, Min Zheng, Hideaki Miyachi, Iris Chen-Yin Lai, S Renée Marshall, Smita Jha and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lauren C S KoleDepartment of Dermatology, University of Alabama at Birmingham, 500 22nd St S, Birmingham, AL, 35233, USA. laurenkole@uabmc.edu.ORCID http://orcid.org/0000-0001-5552-8193
Yayoi TadaDepartment of Dermatology, Teikyo University School of Medicine, Tokyo, Japan.
Sascha GerdesPsoriasis Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany.
Alice B GottliebDepartment of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA.
Matthias AugustinInstitute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Min ZhengDepartment of Dermatology, Second Affiliated Hospital-Zhejiang University School of Medicine, Hangzhou, China.
Hideaki MiyachiCenter for Next Generation of Community Health, Chiba University Hospital, Chiba, Japan.
Iris Chen-Yin LaiDepartment of Pediatrics, National Taiwan University Hospital, Taipei City, Taiwan.
S Renée MarshallBoehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.
Smita JhaBoehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.
Ferhal KüçükosmanBoehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany.
Gang WangDepartment of Dermatology, Xijing Hospital-Fourth Military Medical University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeneralized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease that significantly impacts patients' quality of life (QoL). A multinational panel of patients with GPP participated in surveys and interviews, with the aim to assess the impact of chronic symptoms and GPP flares on QoL and well-being, and to better understand the resources and support that patients need.

methodsPatients (aged 18-65 years) with a confirmed diagnosis of GPP (> 1 month), who had experienced ≥ 1 flare in the past year and were receiving active treatment for GPP were recruited through databases and healthcare professionals (HCPs).

resultsA total of 18 patients (female, n = 15) participated in the study (USA, n = 7; Germany, n = 4; China, n = 4; and Japan, n = 3). Comorbidities included plaque psoriasis (n = 5), psoriatic arthritis (n = 3), and palmoplantar pustulosis (n = 1). Most patients (94%) were receiving active treatment for GPP, including biologics, immunosuppressants (non-biologic), retinoids, and steroids. Itchiness was the most prevalent symptom (82%), followed by dryness (75%), erythema (70%), and fatigue (65%). The scalp, arms, and palms of hands were the most affected areas. Most patients interviewed (80%) reported chronic symptoms, with itchy and dry skin and joint pain being the most frequent. Dermatology Life Quality Index scores indicated a moderate to extremely large impact on QoL in nine patients (50%). Chronic symptoms significantly impacted activities of daily life in 60% of patients. Chronic symptoms and flares negatively affected the psychological well-being of patients (mean General Health Questionnaire-12 score: 15 and 17, respectively). Patients employed self-care strategies, painkillers, and dietary modifications to manage symptoms, sometimes under the guidance of HCPs.

conclusionThis study highlights the impact of GPP on patients' QoL and physical and psychological well-being, due to chronic symptoms that persist despite current treatments. It emphasizes the need for continuous treatment of GPP and the importance of additional resources and support networks for patients.

Indexed as

BurdenChronic symptomsGeneralized pustular psoriasisInterviewPatients’ perspectiveQuality of lifeSurvey

Identifiers

PMID40775186
PMCPMC12454240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.